• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Norges miljø- og biovitenskapelige universitet
  • Faculty of Chemistry, Biotechnology and Food Science (KBM)
  • Master's theses (KBM)
  • View Item
  •   Home
  • Norges miljø- og biovitenskapelige universitet
  • Faculty of Chemistry, Biotechnology and Food Science (KBM)
  • Master's theses (KBM)
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Identification and validation of a novel biomarker for tankyrase inhibition in selected carcinoma cells

Moghal, Aisha Rehman
Master thesis
Thumbnail
View/Open
Rehman 04.02.2015.pdf (3.372Mb)
URI
http://hdl.handle.net/11250/281098
Date
2015-04-09
Metadata
Show full item record
Collections
  • Master's theses (KBM) [949]
Abstract
Tankyrase is a key regulator of cell signaling and metabolism [1]. Tankyrase is a catalytic

enzyme that modifies protein turn-over through a post translational modification called

poly(ADP)-ribosylation [1]. One of the central target proteins of tankyrase mediated

poly(ADP)-ribosylation is AXIN1/2 that regulate the canonical WNT/β-catenin pathway

[1][2][3]. Tankyrase inhibition leads to reduced cell growth accompanied with reduced levels

of β-catenin, the key mediator of the canonical WNT/β-catenin pathway, in selected cancer

cell lines [3][4]. However, in several other cancer cell lines, growth reduction by tankyrase

inhibition appears to be independent of altered canonical WNT/β-catenin pathway activity [4].

With the aim of identifying a more general biomarker for tankyrase inhibition, 660 tumor cell

lines were screened for sensitivity to the novel tankyrase inhibitor G007-LK. Among the

cancer cell lines that exhibited growth alteration in response to G007-LK treatment, five cell

lines were selected for further analysis: ABC-1, a non-small-cell lung cancer cell line;

OVCAR-4, an ovarian cancer cell line; A-498, a renal cancer cell line; COLO320DM and

SW480, both colon cancer cell lines.

An expression profile analysis revealed B-cell lymphoma 2 modifying factor (BMF) to be

strongly upregulated in the highly G007-LK sensitive cell line ABC-1. This upregulation was

not accompanied with altered AXIN2 mRNA expression, a hallmark of canonical WNT

signaling [5]. We found that BMF transcription, was upregulated in ABC-1, COLO320DM,

OVCAR-4 and SW480 cells at 24 and 72 hours after exposure to 1 μM of the tankyrase

inhibitor G007-LK (Fig. 3-2A). In A498 cells, an upregulation of BMF transcripts was only

observed at 24 hours (Fig. 3-2A). The upregulation of BMF was accompanied with a downregulation

of AXIN2 transcription in COLO320DM, OVCAR-4 and SW480 cells (Fig. 3-2A).

All selected cancer cell lines show AXIN1 protein stabilization upon tankyrase inhibition at

72 h of G007-LK treatment, while only SW480 and COLO320DM also show a clear downregulation

of β-catenin (Fig. 3-2B, 3-4B).

AMPK-activation has been implicated in the activation of BMF transcription [6] and

upregulated phosphorylated-AMPKα (Thr172) protein levels display AMPK activation [7].

We were not able to detect alterations in phosphorylated-AMPKα (Thr172) protein levels in

G007-LK treated ABC-1 cells (Fig. 3-3B). Also in COLO320DM cells, total APMK protein

levels were unaltered by tankyrase inhibition, but phosphorylated AMPKα (Thr172) protein

levels were substantially raised upon 72 h of G007-LK exposure (Fig. 3-4B, right). In

contrast, total AMPKα levels were reduced by tankyrase inhibition in BMF depleted

COLO320DM cells, compared to cells treated with BMF esiRNA. However, increased

phosphorylated AMPKα (Thr172) protein levels were still seen. In conclusion, tankyrase

inhibition affected AMPK protein levels only in the absence of BMF, again compared to

cells treated with BMF esiRNA. However, G007-LK increased phosphorylated AMPKα

(Thr172) protein levels independent of BMF (Fig. 3-4B, right). To sum up: (i) We established BMF transcripts as potentially broader biomarkers for

tankyrase inhibition in cancer cells compared to the previously used β-catenin biomarker (Fig.

3-2A, 3-2B), (ii) we show a regulatory interaction between BMF and AMPK in

COLO320DM that depends on tankyrase inhibitor G007-LK activity (Fig. 3-4B, right) and

(iii) we finally demonstrate that AMPK phosphorylation (at Thr172) is increased by G007-

LK-mediated TNKS1/2 inhibition, perhaps through AXIN1 stabilization, in COLO320DM

(Fig. 3-4B, right).
Publisher
Norwegian University of Life Sciences, Ås

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit